SEARCH

SEARCH BY CITATION

References

  • 1
    Perlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52: 889900.
  • 2
    U.S. Food and Drug Administration. Chronic hepatitis C virus infection: developing direct-acting antiviral agents for treatment. Draft Guidance for Industry; September 2010.
  • 3
    Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. HEPATOLOGY 2006; 43: 954960.
  • 4
    Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451458.
  • 5
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. HEPATOLOGY 2009; 49: 13351374.
  • 6
    Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 11951206.
  • 7
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 12071217.
  • 8
    Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Eng J Med 2011; 364: 24172428.
  • 9
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Eng J Med 2011; 364: 24052416.
  • 10
    U.S. Food and Drug Administration. Antiviral Drug Advisory Committee Meeting and Briefing Materials for Boceprevir, April 27, 2011.
  • 11
    U.S. Food and Drug Administration. Antiviral Drug Advisory Committee Meeting and Briefing Materials for Telaprevir, April 28, 2011.
  • 12
    Victrelis (boceprevir) Capsules. US Prescribing Information. Whitehouse Station, NJ: Merck; May 2011.
  • 13
    Incivek (telaprevir) Film Coated Tablets. US Prescribing Information. Cambridge, MA: Vertex Pharmaceuticals; May 2011.
  • 14
    Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705716.
  • 15
    McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 18271838.
  • 16
    Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 18391850.
  • 17
    COBAS TaqMan HCV Test, v2.0, For Use With The High Pure System (Doc Rev. 1.0). U.S. Package Insert. Branchburg, NJ: Roche Molecular Systems; September 2010.
  • 18
    Veerapu NS, Raghuraman S, Liang TJ, Heller T, Rehermann B. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Gastroenterology 2011; 140: 676685.
  • 19
    Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821829.
  • 20
    Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453463.